Epidemiology of clinically isolated methicillin-resistant Staphylococcus aureus (MRSA) and its susceptibility to linezolid and vancomycin in Egypt: a systematic review with meta-analysis

Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen that causes severe morbidity and mortality worldwide. For the establishment of national strategies to combat MRSA infection in each country, accurate and current statistics characterizing the epidemiology of MRSA are e...

Full description

Saved in:
Bibliographic Details
Published inBMC infectious diseases Vol. 23; no. 1; pp. 263 - 15
Main Authors Azzam, Ahmed, Khaled, Heba, Mosa, Maha, Refaey, Neveen, AlSaifi, Mohammed, Elsisi, Sarah, Elagezy, Fatma Khaled, Mohsen, May
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 26.04.2023
BioMed Central
BMC
Subjects
Analysis
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Antibiotics
Antimicrobial agents
Bacterial Proteins - genetics
Cefoxitin
Cefoxitin - therapeutic use
Cefoxitin disc diffusion
Clinical isolates
Diffusion
Diffusion rate
Disease control
Disease susceptibility
Dosage and administration
Drug resistance
Drug resistance in microorganisms
Egypt
Egypt - epidemiology
Epidemiology
Health aspects
Hospital costs
Humans
Infectious diseases
Linezolid
Linezolid - pharmacology
Linezolid - therapeutic use
Literature reviews
MecA protein
Medical personnel
Meta-analysis
Methicillin
Methicillin-resistant Staphylococcus aureus
Methicillin-Resistant Staphylococcus aureus - genetics
Microbial Sensitivity Tests
Morbidity
Mortality
MRSA
Nosocomial infection
Oxacillin
Oxacillin disc diffusion
Penicillin
Penicillin-Binding Proteins - genetics
Prevalence
Prevalence studies (Epidemiology)
Prevention
Prohibition
Public health
Risk factors
Sensitivity analysis
Staphylococcal Infections - drug therapy
Staphylococcus aureus
Staphylococcus aureus infections
Staphylococcus infections
Statistical analysis
Subgroups
Systematic review
Vancomycin
Vancomycin - pharmacology
Vancomycin - therapeutic use
Egypt
United Kingdom > UK
Linezolid
Oxacillin disc diffusion
Prevalence
Cefoxitin disc diffusion
Methicillin-resistant Staphylococcus aureus
Egypt
MRSA
Vancomycin
Epidemiology
PCR
Online AccessGet full text

Cover

Abstract Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen that causes severe morbidity and mortality worldwide. For the establishment of national strategies to combat MRSA infection in each country, accurate and current statistics characterizing the epidemiology of MRSA are essential. The purpose of this study was to determine the prevalence of MRSA among Staphylococcus aureus clinical isolates in Egypt. In addition, we aimed to compare different diagnostic methods for MRSA and determine the pooled resistance rate of linezolid and vancomycin to MRSA. To address this knowledge gap, we conducted a systematic review with meta-analysis. A comprehensive literature search from inception to October 2022 of the following databases was performed: MEDLINE [PubMed], Scopus, Google Scholar, and Web of Science. The review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement. Based on the random effects model, results were reported as proportions with a 95% confidence interval (CI). Analyses of the subgroups were conducted. A sensitivity analysis was conducted to test the robustness of the results. A total of sixty-four (64) studies were included in the present meta-analysis, with a total sample size of 7171 subjects. The overall prevalence of MRSA was 63% [95% CI: 55-70]. Fifteen (15) studies used both PCR and cefoxitin disc diffusion for MRSA detection, with a pooled prevalence rate of 67% [95% CI: 54-79] and 67% [95% CI: 55-80], respectively. While nine (9) studies used both PCR and Oxacillin disc diffusion for MRSA detection, the pooled prevalences were 60% [95% CI: 45-75] and 64% [95% CI: 43-84], respectively. Furthermore, MRSA appeared to be less resistant to linezolid than vancomycin, with a pooled resistance rate of 5% [95% CI: 2-8] to linezolid and 9% [95% CI: 6-12] to vancomycin, respectively. Our review highlights Egypt's high MRSA prevalence. The cefoxitin disc diffusion test results were found to be consistent with PCR identification of the mecA gene. A prohibition on antibiotic self-medication and efforts to educate healthcare workers and patients about the proper use of antimicrobials may be required to prevent further increases.
AbstractList Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen that causes severe morbidity and mortality worldwide. For the establishment of national strategies to combat MRSA infection in each country, accurate and current statistics characterizing the epidemiology of MRSA are essential. The purpose of this study was to determine the prevalence of MRSA among Staphylococcus aureus clinical isolates in Egypt. In addition, we aimed to compare different diagnostic methods for MRSA and determine the pooled resistance rate of linezolid and vancomycin to MRSA. To address this knowledge gap, we conducted a systematic review with meta-analysis.BACKGROUNDMethicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen that causes severe morbidity and mortality worldwide. For the establishment of national strategies to combat MRSA infection in each country, accurate and current statistics characterizing the epidemiology of MRSA are essential. The purpose of this study was to determine the prevalence of MRSA among Staphylococcus aureus clinical isolates in Egypt. In addition, we aimed to compare different diagnostic methods for MRSA and determine the pooled resistance rate of linezolid and vancomycin to MRSA. To address this knowledge gap, we conducted a systematic review with meta-analysis.A comprehensive literature search from inception to October 2022 of the following databases was performed: MEDLINE [PubMed], Scopus, Google Scholar, and Web of Science. The review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement. Based on the random effects model, results were reported as proportions with a 95% confidence interval (CI). Analyses of the subgroups were conducted. A sensitivity analysis was conducted to test the robustness of the results.METHODSA comprehensive literature search from inception to October 2022 of the following databases was performed: MEDLINE [PubMed], Scopus, Google Scholar, and Web of Science. The review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement. Based on the random effects model, results were reported as proportions with a 95% confidence interval (CI). Analyses of the subgroups were conducted. A sensitivity analysis was conducted to test the robustness of the results.A total of sixty-four (64) studies were included in the present meta-analysis, with a total sample size of 7171 subjects. The overall prevalence of MRSA was 63% [95% CI: 55-70]. Fifteen (15) studies used both PCR and cefoxitin disc diffusion for MRSA detection, with a pooled prevalence rate of 67% [95% CI: 54-79] and 67% [95% CI: 55-80], respectively. While nine (9) studies used both PCR and Oxacillin disc diffusion for MRSA detection, the pooled prevalences were 60% [95% CI: 45-75] and 64% [95% CI: 43-84], respectively. Furthermore, MRSA appeared to be less resistant to linezolid than vancomycin, with a pooled resistance rate of 5% [95% CI: 2-8] to linezolid and 9% [95% CI: 6-12] to vancomycin, respectively.RESULTSA total of sixty-four (64) studies were included in the present meta-analysis, with a total sample size of 7171 subjects. The overall prevalence of MRSA was 63% [95% CI: 55-70]. Fifteen (15) studies used both PCR and cefoxitin disc diffusion for MRSA detection, with a pooled prevalence rate of 67% [95% CI: 54-79] and 67% [95% CI: 55-80], respectively. While nine (9) studies used both PCR and Oxacillin disc diffusion for MRSA detection, the pooled prevalences were 60% [95% CI: 45-75] and 64% [95% CI: 43-84], respectively. Furthermore, MRSA appeared to be less resistant to linezolid than vancomycin, with a pooled resistance rate of 5% [95% CI: 2-8] to linezolid and 9% [95% CI: 6-12] to vancomycin, respectively.Our review highlights Egypt's high MRSA prevalence. The cefoxitin disc diffusion test results were found to be consistent with PCR identification of the mecA gene. A prohibition on antibiotic self-medication and efforts to educate healthcare workers and patients about the proper use of antimicrobials may be required to prevent further increases.CONCLUSIONOur review highlights Egypt's high MRSA prevalence. The cefoxitin disc diffusion test results were found to be consistent with PCR identification of the mecA gene. A prohibition on antibiotic self-medication and efforts to educate healthcare workers and patients about the proper use of antimicrobials may be required to prevent further increases.
Abstract Background Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen that causes severe morbidity and mortality worldwide. For the establishment of national strategies to combat MRSA infection in each country, accurate and current statistics characterizing the epidemiology of MRSA are essential. The purpose of this study was to determine the prevalence of MRSA among Staphylococcus aureus clinical isolates in Egypt. In addition, we aimed to compare different diagnostic methods for MRSA and determine the pooled resistance rate of linezolid and vancomycin to MRSA. To address this knowledge gap, we conducted a systematic review with meta-analysis. Methods A comprehensive literature search from inception to October 2022 of the following databases was performed: MEDLINE [PubMed], Scopus, Google Scholar, and Web of Science. The review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement. Based on the random effects model, results were reported as proportions with a 95% confidence interval (CI). Analyses of the subgroups were conducted. A sensitivity analysis was conducted to test the robustness of the results. Results A total of sixty-four (64) studies were included in the present meta-analysis, with a total sample size of 7171 subjects. The overall prevalence of MRSA was 63% [95% CI: 55–70]. Fifteen (15) studies used both PCR and cefoxitin disc diffusion for MRSA detection, with a pooled prevalence rate of 67% [95% CI: 54–79] and 67% [95% CI: 55–80], respectively. While nine (9) studies used both PCR and Oxacillin disc diffusion for MRSA detection, the pooled prevalences were 60% [95% CI: 45–75] and 64% [95% CI: 43–84], respectively. Furthermore, MRSA appeared to be less resistant to linezolid than vancomycin, with a pooled resistance rate of 5% [95% CI: 2–8] to linezolid and 9% [95% CI: 6–12] to vancomycin, respectively. Conclusion Our review highlights Egypt's high MRSA prevalence. The cefoxitin disc diffusion test results were found to be consistent with PCR identification of the mecA gene. A prohibition on antibiotic self-medication and efforts to educate healthcare workers and patients about the proper use of antimicrobials may be required to prevent further increases.
Background Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen that causes severe morbidity and mortality worldwide. For the establishment of national strategies to combat MRSA infection in each country, accurate and current statistics characterizing the epidemiology of MRSA are essential. The purpose of this study was to determine the prevalence of MRSA among Staphylococcus aureus clinical isolates in Egypt. In addition, we aimed to compare different diagnostic methods for MRSA and determine the pooled resistance rate of linezolid and vancomycin to MRSA. To address this knowledge gap, we conducted a systematic review with meta-analysis. Methods A comprehensive literature search from inception to October 2022 of the following databases was performed: MEDLINE [PubMed], Scopus, Google Scholar, and Web of Science. The review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement. Based on the random effects model, results were reported as proportions with a 95% confidence interval (CI). Analyses of the subgroups were conducted. A sensitivity analysis was conducted to test the robustness of the results. Results A total of sixty-four (64) studies were included in the present meta-analysis, with a total sample size of 7171 subjects. The overall prevalence of MRSA was 63% [95% CI: 55-70]. Fifteen (15) studies used both PCR and cefoxitin disc diffusion for MRSA detection, with a pooled prevalence rate of 67% [95% CI: 54-79] and 67% [95% CI: 55-80], respectively. While nine (9) studies used both PCR and Oxacillin disc diffusion for MRSA detection, the pooled prevalences were 60% [95% CI: 45-75] and 64% [95% CI: 43-84], respectively. Furthermore, MRSA appeared to be less resistant to linezolid than vancomycin, with a pooled resistance rate of 5% [95% CI: 2-8] to linezolid and 9% [95% CI: 6-12] to vancomycin, respectively. Conclusion Our review highlights Egypt's high MRSA prevalence. The cefoxitin disc diffusion test results were found to be consistent with PCR identification of the mecA gene. A prohibition on antibiotic self-medication and efforts to educate healthcare workers and patients about the proper use of antimicrobials may be required to prevent further increases. Keywords: Prevalence, Epidemiology, Methicillin-resistant Staphylococcus aureus, MRSA, Cefoxitin disc diffusion, Oxacillin disc diffusion, PCR, Linezolid, Vancomycin, Egypt
Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen that causes severe morbidity and mortality worldwide. For the establishment of national strategies to combat MRSA infection in each country, accurate and current statistics characterizing the epidemiology of MRSA are essential. The purpose of this study was to determine the prevalence of MRSA among Staphylococcus aureus clinical isolates in Egypt. In addition, we aimed to compare different diagnostic methods for MRSA and determine the pooled resistance rate of linezolid and vancomycin to MRSA. To address this knowledge gap, we conducted a systematic review with meta-analysis. A comprehensive literature search from inception to October 2022 of the following databases was performed: MEDLINE [PubMed], Scopus, Google Scholar, and Web of Science. The review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement. Based on the random effects model, results were reported as proportions with a 95% confidence interval (CI). Analyses of the subgroups were conducted. A sensitivity analysis was conducted to test the robustness of the results. A total of sixty-four (64) studies were included in the present meta-analysis, with a total sample size of 7171 subjects. The overall prevalence of MRSA was 63% [95% CI: 55-70]. Fifteen (15) studies used both PCR and cefoxitin disc diffusion for MRSA detection, with a pooled prevalence rate of 67% [95% CI: 54-79] and 67% [95% CI: 55-80], respectively. While nine (9) studies used both PCR and Oxacillin disc diffusion for MRSA detection, the pooled prevalences were 60% [95% CI: 45-75] and 64% [95% CI: 43-84], respectively. Furthermore, MRSA appeared to be less resistant to linezolid than vancomycin, with a pooled resistance rate of 5% [95% CI: 2-8] to linezolid and 9% [95% CI: 6-12] to vancomycin, respectively. Our review highlights Egypt's high MRSA prevalence. The cefoxitin disc diffusion test results were found to be consistent with PCR identification of the mecA gene. A prohibition on antibiotic self-medication and efforts to educate healthcare workers and patients about the proper use of antimicrobials may be required to prevent further increases.
Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen that causes severe morbidity and mortality worldwide. For the establishment of national strategies to combat MRSA infection in each country, accurate and current statistics characterizing the epidemiology of MRSA are essential. The purpose of this study was to determine the prevalence of MRSA among Staphylococcus aureus clinical isolates in Egypt. In addition, we aimed to compare different diagnostic methods for MRSA and determine the pooled resistance rate of linezolid and vancomycin to MRSA. To address this knowledge gap, we conducted a systematic review with meta-analysis. A comprehensive literature search from inception to October 2022 of the following databases was performed: MEDLINE [PubMed], Scopus, Google Scholar, and Web of Science. The review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement. Based on the random effects model, results were reported as proportions with a 95% confidence interval (CI). Analyses of the subgroups were conducted. A sensitivity analysis was conducted to test the robustness of the results. A total of sixty-four (64) studies were included in the present meta-analysis, with a total sample size of 7171 subjects. The overall prevalence of MRSA was 63% [95% CI: 55-70]. Fifteen (15) studies used both PCR and cefoxitin disc diffusion for MRSA detection, with a pooled prevalence rate of 67% [95% CI: 54-79] and 67% [95% CI: 55-80], respectively. While nine (9) studies used both PCR and Oxacillin disc diffusion for MRSA detection, the pooled prevalences were 60% [95% CI: 45-75] and 64% [95% CI: 43-84], respectively. Furthermore, MRSA appeared to be less resistant to linezolid than vancomycin, with a pooled resistance rate of 5% [95% CI: 2-8] to linezolid and 9% [95% CI: 6-12] to vancomycin, respectively. Our review highlights Egypt's high MRSA prevalence. The cefoxitin disc diffusion test results were found to be consistent with PCR identification of the mecA gene. A prohibition on antibiotic self-medication and efforts to educate healthcare workers and patients about the proper use of antimicrobials may be required to prevent further increases.
BackgroundMethicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen that causes severe morbidity and mortality worldwide. For the establishment of national strategies to combat MRSA infection in each country, accurate and current statistics characterizing the epidemiology of MRSA are essential. The purpose of this study was to determine the prevalence of MRSA among Staphylococcus aureus clinical isolates in Egypt. In addition, we aimed to compare different diagnostic methods for MRSA and determine the pooled resistance rate of linezolid and vancomycin to MRSA. To address this knowledge gap, we conducted a systematic review with meta-analysis.MethodsA comprehensive literature search from inception to October 2022 of the following databases was performed: MEDLINE [PubMed], Scopus, Google Scholar, and Web of Science. The review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement. Based on the random effects model, results were reported as proportions with a 95% confidence interval (CI). Analyses of the subgroups were conducted. A sensitivity analysis was conducted to test the robustness of the results.ResultsA total of sixty-four (64) studies were included in the present meta-analysis, with a total sample size of 7171 subjects. The overall prevalence of MRSA was 63% [95% CI: 55–70]. Fifteen (15) studies used both PCR and cefoxitin disc diffusion for MRSA detection, with a pooled prevalence rate of 67% [95% CI: 54–79] and 67% [95% CI: 55–80], respectively. While nine (9) studies used both PCR and Oxacillin disc diffusion for MRSA detection, the pooled prevalences were 60% [95% CI: 45–75] and 64% [95% CI: 43–84], respectively. Furthermore, MRSA appeared to be less resistant to linezolid than vancomycin, with a pooled resistance rate of 5% [95% CI: 2–8] to linezolid and 9% [95% CI: 6–12] to vancomycin, respectively.ConclusionOur review highlights Egypt's high MRSA prevalence. The cefoxitin disc diffusion test results were found to be consistent with PCR identification of the mecA gene. A prohibition on antibiotic self-medication and efforts to educate healthcare workers and patients about the proper use of antimicrobials may be required to prevent further increases.
ArticleNumber 263
Audience Academic
Author Khaled, Heba
Elsisi, Sarah
Mosa, Maha
Elagezy, Fatma Khaled
Mohsen, May
AlSaifi, Mohammed
Azzam, Ahmed
Refaey, Neveen
Author_xml – sequence: 1
  givenname: Ahmed
  surname: Azzam
  fullname: Azzam, Ahmed
– sequence: 2
  givenname: Heba
  surname: Khaled
  fullname: Khaled, Heba
– sequence: 3
  givenname: Maha
  surname: Mosa
  fullname: Mosa, Maha
– sequence: 4
  givenname: Neveen
  surname: Refaey
  fullname: Refaey, Neveen
– sequence: 5
  givenname: Mohammed
  surname: AlSaifi
  fullname: AlSaifi, Mohammed
– sequence: 6
  givenname: Sarah
  surname: Elsisi
  fullname: Elsisi, Sarah
– sequence: 7
  givenname: Fatma Khaled
  surname: Elagezy
  fullname: Elagezy, Fatma Khaled
– sequence: 8
  givenname: May
  surname: Mohsen
  fullname: Mohsen, May
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37101125$$D View this record in MEDLINE/PubMed
BookMark eNqNk9tu1DAQhiNURA_wAlwgS9y0Fyk-xBubG1RVBVYqqtQFbq2J4-y6cuIldlrCo_F0ON1SuhVCKJFs2d_8mcz8s5_tdL4zWfaS4GNCxOxNIFSUMseU5VhQTHP6JNsjRUlyylix82C_m-2HcIUxKQWVz7JdVhJMCOV72c-zta1Na73zyxH5BmlnO6vBuRHZ4B1EU6PWxJXV1qWrvDfBhghdRIsI69XovPZaDwHB0Ju0HH66XJwcIehqZGNAYQjarKOtrLNxRNGjJGJ-eGfrW-YaOu3bUdsOpfdsOa7jWwQojCGaFqLVqDfX1tygGxtXUyKQQwduTEk8z5424IJ5cbceZF_en30-_ZifX3yYn56c53rGaMyl4AyqpmoYYMmLmjJDiQQoGTG0qlnNpTBclqIGoakmrCpwhRuoKi1LajA7yOYb3drDlVr3toV-VB6suj3w_VJBnzJ1RoGUQmjTcF2yQpa1gEpzIIQ3BZ9VjCetdxut9VC1ptamiz24LdHtm86u1NJfq9QvVnBKksLhnULvvw0mRNXaVGLnoDN-CIoKPJMy9XxK_PUj9MoPfareRBHOuRAF_UMtIf2B7RqfPqwnUXVSJgOVOLGJOv4LlZ7JPDr5srHpfCvgaCsgMdF8j0sYQlDzxeX_sxdft9lXDyt4X7rflk4A3QC69yH0prlHCFbT3KjN3Kg0N-p2btRUBPEoSNuY7OenLlj3r9Bf11ceJw
CitedBy_id crossref_primary_10_1186_s12879_024_10047_2
crossref_primary_10_54751_revistafoco_v16n10_167
crossref_primary_10_1007_s00203_024_03965_x
crossref_primary_10_4103_jcmrp_jcmrp_56_23
crossref_primary_10_3389_fcimb_2024_1403219
crossref_primary_10_3389_fmicb_2024_1422574
crossref_primary_10_1016_j_ram_2024_10_001
crossref_primary_10_1038_s41598_024_56254_4
crossref_primary_10_1016_j_biopha_2024_116228
crossref_primary_10_1038_s41598_024_60924_8
crossref_primary_10_1155_2024_8832448
crossref_primary_10_1186_s12920_024_01979_4
crossref_primary_10_1016_j_onehlt_2024_100910
crossref_primary_10_2147_IDR_S465951
crossref_primary_10_5812_jjm_144398
crossref_primary_10_4103_ajop_ajop_12_24
crossref_primary_10_1007_s12088_024_01228_3
Cites_doi 10.3855/jidc.15833
10.1155/2014/650328
10.13005/BBRA/2739
10.21608/AJBS.2020.80481
10.22207/JPAM.13.4.23
10.4314/ajb.v11i99
10.1186/S12941-021-00459-2/TABLES/3
10.1016/J.EPAG.2017.09.001
10.21608/EJBO.2017.1506.1118
10.3390/antibiotics10050488
10.7537/marsnsj160618.08
10.1111/J.1469-0691.2010.03365.X
10.21608/mid.2022.115351.1232
10.1016/S0924-8579(07)71658-8
10.1001/ARCHINTE.162.19.2229
10.1086/345476/2/36-1-53-FIG002.GIF
10.12816/0037025
10.1128/CMR.00081-09
10.1371/journal.pone.0148175
10.22207/JPAM.14.4.56
10.4103/0974-2727.105587
10.18683/GERMS.2018.1140
10.5897/AJMR12.1430
10.12816/0053809
10.1186/s42506-020-00065-8
10.4314/tjpr.v13i8.7
10.1017/ICE.2015.22
10.1016/S0255-0857(21)01748-5
10.3855/jidc.3105
10.1016/J.AJIC.2011.04.009
10.1089/SUR.2013.212
10.1016/J.AJIC.2017.03.013
10.9734/BMRJ/2015/15477
10.1007/S00580-018-2858-3/TABLES/1
10.3823/784
10.21608/EJBO.2021.47561.1576
10.1089/mdr.2020.0361
10.1111/ijcp.14081
10.18502/ijm.v14i1.8802
10.12816/0046236
10.1093/qjmed/hcy200.117
10.1038/s41598-020-60825-6
10.26719/2014.20.4.273
10.21608/zjps.2016.38183
10.14715/cmb/2016.62.2.16
10.1016/J.BJID.2012.08.004
10.18683/GERMS.2020.1221
10.12980/APJTB.4.2014C423
10.1016/J.JGAR.2015.11.010
10.22207/JPaM.12.3.07
10.2174/18742858-v16-e2204210
10.1093/jac/dkw052
10.5897/AJMR12.2333
10.1016/J.JCLINEPI.2014.03.003
10.22207/JPAM.13.2.21
10.21608/AIJPMS.2021.69608.1058
10.21608/JAVS.2021.159379
10.21608/EJBO.2015.223
10.5897/ajmr2013.2525
10.4103/ijpvm.IJPVM_320_18
10.4103/1110-2098.202519
10.21608/MID.2020.41062.1057
10.1136/EJHPHARM-2016-001032
10.21608/APS.2019.17391.1014
10.1128/AAC.02803-15
10.21608/MID.2022.155274.1366
10.51429/EJMM29313
10.21608/EJBO.2018.4221.1187
10.21608/ZJPS.2016.38164
10.1016/j.genrep.2021.101334
10.4314/ajb.v11i94
10.4236/OJMM.2019.93013
10.1128/JB.158.2.513-516.1984
10.1016/J.MICPATH.2017.11.021
10.1504/IJIS.2009.023564
10.4103/0377-4929.59189
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
IOV
ISR
3V.
7QL
7T2
7U9
7X7
7XB
88E
8C1
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BENPR
C1K
CCPQU
COVID
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
M7N
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12879-023-08202-2
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Opposing Viewpoints
Gale In Context: Science
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Health and Safety Science Abstracts (Full archive)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One
Coronavirus Research Database
ProQuest Central
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Open Access资源_DOAJ
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
Health & Safety Science Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


MEDLINE

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1471-2334
EndPage 15
ExternalDocumentID oai_doaj_org_article_a9988cef5c73497d8abc5a115f456b35
PMC10134521
A747170815
37101125
10_1186_s12879_023_08202_2
Genre Meta-Analysis
Systematic Review
Journal Article
GeographicLocations Egypt
United Kingdom--UK
GeographicLocations_xml – name: Egypt
– name: United Kingdom--UK
GrantInformation_xml – fundername: ;
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8C1
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
IOV
ISR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7QL
7T2
7U9
7XB
8FK
AZQEC
C1K
COVID
DWQXO
H94
K9.
M7N
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c632t-9853abfbf3a0954d23e219aa731e2bd3d598e5978da8c2c13b40b0fabbc972e03
IEDL.DBID M48
ISSN 1471-2334
IngestDate Wed Aug 27 01:22:43 EDT 2025
Thu Aug 21 18:37:48 EDT 2025
Fri Jul 11 11:22:24 EDT 2025
Fri Jul 25 21:27:36 EDT 2025
Tue Jun 17 21:35:29 EDT 2025
Tue Jun 10 20:29:41 EDT 2025
Fri Jun 27 05:59:38 EDT 2025
Fri Jun 27 06:12:57 EDT 2025
Thu Jan 02 22:53:07 EST 2025
Thu Apr 24 22:53:29 EDT 2025
Tue Jul 01 03:10:42 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Linezolid
Oxacillin disc diffusion
Prevalence
Cefoxitin disc diffusion
Methicillin-resistant Staphylococcus aureus
Egypt
MRSA
Vancomycin
Epidemiology
PCR
Language English
License 2023. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c632t-9853abfbf3a0954d23e219aa731e2bd3d598e5978da8c2c13b40b0fabbc972e03
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12879-023-08202-2
PMID 37101125
PQID 2815558842
PQPubID 42582
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_a9988cef5c73497d8abc5a115f456b35
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10134521
proquest_miscellaneous_2806993340
proquest_journals_2815558842
gale_infotracmisc_A747170815
gale_infotracacademiconefile_A747170815
gale_incontextgauss_ISR_A747170815
gale_incontextgauss_IOV_A747170815
pubmed_primary_37101125
crossref_primary_10_1186_s12879_023_08202_2
crossref_citationtrail_10_1186_s12879_023_08202_2
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-04-26
PublicationDateYYYYMMDD 2023-04-26
PublicationDate_xml – month: 04
  year: 2023
  text: 2023-04-26
  day: 26
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC infectious diseases
PublicationTitleAlternate BMC Infect Dis
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References BJ Hartman (8202_CR1) 1984; 158
JK El-Jakee (8202_CR53) 2011; 7
A Fikry (8202_CR79) 2021; 6
L Metwally (8202_CR33) 2014; 20
MH EL-gayar (8202_CR54) 2014; 5
RE Mendes (8202_CR94) 2016; 71
AA Mathews (8202_CR87) 2010; 53
M Mashaly (8202_CR56) 2019; 28
AE Taha (8202_CR71) 2019; 13
SH Ahmed (8202_CR66) 2011; 20
A Sheneef (8202_CR55) 2017; 26
A Ali (8202_CR64) 2022
MM Salem-Bekhit (8202_CR74) 2014; 13
M Sadaka (8202_CR32) 2009; 3
RE Nelson (8202_CR8) 2015; 36
SI Blot (8202_CR7) 2002; 162
SM Samy (8202_CR25) 2018; 27
AS Sleem (8202_CR63) 2022; 3
MM Pillai (8202_CR91) 2012; 4
H Askar (8202_CR31) 2016; 6
SH Ahmed (8202_CR77) 2019; 59
RM El-Hawy (8202_CR81) 2017; 24
H Koupahi (8202_CR89) 2016; 11
S Taher (8202_CR69) 2009; 18
MM Mohamed (8202_CR21) 2016; 29
IM El Karamany (8202_CR27) 2013; 7
GH Ali (8202_CR20) 2021; 25
NY Omar (8202_CR22) 2014; 2014
I Wali (8202_CR34) 2011; 2
R Soodabeh (8202_CR86) 2013; 7
N Elsayed (8202_CR41) 2018; 8
AAE Alfeky (8202_CR37) 2022; 16
YA Al Zawahry (8202_CR76) 2018; 58
AA Elsayed (8202_CR84) 2021; 75
YE Abdelmawgoud (8202_CR83) 2022; 62
EE Hafez (8202_CR61) 2009; 1
SI Mostafa (8202_CR62) 2013; 7
D Souverein (8202_CR9) 2016; 11
MA El-Sweify (8202_CR40) 2021; 2
EM Hefzy (8202_CR35) 2016; 25
X Zhen (8202_CR6) 2020; 10
AM Sultan (8202_CR29) 2019; 13
8202_CR38
EF Ahmed (8202_CR45) 2014; 15
AH Shady (8202_CR51) 2016; 11
MM El-Bouseary (8202_CR30) 2018; 16
FI Sonbol (8202_CR46) 2022; 3
E Askari (8202_CR48) 2012; 15
RM Kishk (8202_CR57) 2019; 09
MM Bendary (8202_CR43) 2016; 62
R Hassan (8202_CR24) 2017; 48
NM Hashem (8202_CR59) 2021; 7
FR Alzahraa Hareidy (8202_CR65) 2022; 2
MR Salem (8202_CR80) 2017; 45
N Torimiro (8202_CR90) 2016; 11
NM Rashwan (8202_CR73) 2006; 15
RK Flamm (8202_CR93) 2016; 60
GI Barakat (8202_CR42) 2016; 4
A El-Essawy (8202_CR28) 2015; 55
AH Elkhyat (8202_CR72) 2020; 29
RH Bassyouni (8202_CR82) 2015; 10
T Saied (8202_CR39) 2011; 39
CRB Youssef (8202_CR52) 2022; 14
N Rizk (8202_CR75) 2007; 2
R Shrief (8202_CR78) 2019; 16
NAE Fahim (8202_CR67) 2021; 96
M Zaki (8202_CR36) 2020; 10
ESH Ibrahim (8202_CR60) 2020; 16
8202_CR47
M Abdel-Mongy (8202_CR17) 2018; 12
SA Refeai (8202_CR49) 2020; 11
SE Cosgrove (8202_CR5) 2003; 36
HR Shebl (8202_CR23) 2020; 14
RA Hashem (8202_CR44) 2013; 7
N Sobhy (8202_CR26) 2012; 16
R El-baz (8202_CR19) 2017; 113
AA Kadry (8202_CR16) 2016; 25
8202_CR4
E El Gemezy (8202_CR68) 2016; 25
8202_CR3
K Anand (8202_CR12) 2009; 27
RH Hassan (8202_CR58) 2017; 65
AM El-Baz (8202_CR50) 2021; 10
D Nair (8202_CR13) 2021; 27
MZ David (8202_CR85) 2010; 23
IM Gould (8202_CR10) 2010; 16
8202_CR11
A Pournajaf (8202_CR92) 2014; 4
MR Pourmand (8202_CR88) 2014; 6
SM Abdelaziz (8202_CR18) 2019; 3
AS Lee (8202_CR2) 2018; 4
JP Hunter (8202_CR15) 2014; 67
8202_CR14
WM Abdelraheem (8202_CR70) 2021; 20
References_xml – volume: 16
  start-page: 795
  issue: 05
  year: 2022
  ident: 8202_CR37
  publication-title: J Infect Dev Ctries
  doi: 10.3855/jidc.15833
– volume: 2014
  start-page: 650328
  year: 2014
  ident: 8202_CR22
  publication-title: Int J Microbiol
  doi: 10.1155/2014/650328
– volume: 16
  start-page: 221
  issue: 2
  year: 2019
  ident: 8202_CR78
  publication-title: Biosci Biotechnol Res Asia
  doi: 10.13005/BBRA/2739
– volume: 16
  start-page: 43
  issue: 1
  year: 2020
  ident: 8202_CR60
  publication-title: African J Biol Sci
  doi: 10.21608/AJBS.2020.80481
– volume: 3
  start-page: 55
  issue: 2
  year: 2009
  ident: 8202_CR32
  publication-title: African J Microbiol Res
– volume: 13
  start-page: 2111
  issue: 4
  year: 2019
  ident: 8202_CR71
  publication-title: J Pure Appl Microbiol
  doi: 10.22207/JPAM.13.4.23
– volume: 11
  start-page: 16494
  issue: 99
  year: 2016
  ident: 8202_CR51
  publication-title: African J Biotechnol
  doi: 10.4314/ajb.v11i99
– volume: 20
  start-page: 1
  issue: 1
  year: 2021
  ident: 8202_CR70
  publication-title: Ann Clin Microbiol Antimicrob
  doi: 10.1186/S12941-021-00459-2/TABLES/3
– volume: 65
  start-page: 127
  issue: 4
  year: 2017
  ident: 8202_CR58
  publication-title: Egypt Pediatr Assoc Gaz
  doi: 10.1016/J.EPAG.2017.09.001
– volume: 58
  start-page: 11
  issue: 1
  year: 2018
  ident: 8202_CR76
  publication-title: Egypt J Bot
  doi: 10.21608/EJBO.2017.1506.1118
– volume: 10
  start-page: 488
  issue: 5
  year: 2021
  ident: 8202_CR50
  publication-title: Antibiot
  doi: 10.3390/antibiotics10050488
– volume: 4
  start-page: 1
  issue: 1
  year: 2018
  ident: 8202_CR2
  publication-title: Nat Rev Dis Prim
– volume: 16
  start-page: 48
  issue: 6
  year: 2018
  ident: 8202_CR30
  publication-title: Nat Sci
  doi: 10.7537/marsnsj160618.08
– volume: 16
  start-page: 1721
  issue: 12
  year: 2010
  ident: 8202_CR10
  publication-title: Clin Microbiol Infect
  doi: 10.1111/J.1469-0691.2010.03365.X
– ident: 8202_CR14
– year: 2022
  ident: 8202_CR64
  publication-title: Microbes Infect Dis
  doi: 10.21608/mid.2022.115351.1232
– volume: 2
  start-page: S519
  issue: 29
  year: 2007
  ident: 8202_CR75
  publication-title: Egypt. Int J Antimicrob Agents.
  doi: 10.1016/S0924-8579(07)71658-8
– volume: 162
  start-page: 2229
  issue: 19
  year: 2002
  ident: 8202_CR7
  publication-title: Arch Intern Med
  doi: 10.1001/ARCHINTE.162.19.2229
– volume: 7
  start-page: 581
  issue: 6
  year: 2011
  ident: 8202_CR53
  publication-title: Glob Vet
– volume: 36
  start-page: 53
  issue: 1
  year: 2003
  ident: 8202_CR5
  publication-title: Clin Infect Dis
  doi: 10.1086/345476/2/36-1-53-FIG002.GIF
– volume: 25
  start-page: 91
  issue: 4
  year: 2016
  ident: 8202_CR35
  publication-title: Egypt J Med Microbiol
  doi: 10.12816/0037025
– volume: 23
  start-page: 616
  issue: 3
  year: 2010
  ident: 8202_CR85
  publication-title: Clin Microbiol Rev
  doi: 10.1128/CMR.00081-09
– volume: 2
  start-page: 81
  issue: 20
  year: 2011
  ident: 8202_CR34
  publication-title: Egypt J Lab Med
– volume: 11
  start-page: e0148175
  issue: 2
  year: 2016
  ident: 8202_CR9
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0148175
– volume: 14
  start-page: 2807
  issue: 4
  year: 2020
  ident: 8202_CR23
  publication-title: J Pure Appl Microbiol
  doi: 10.22207/JPAM.14.4.56
– volume: 7
  start-page: 48
  issue: 4
  year: 2021
  ident: 8202_CR59
  publication-title: AIMS Microbiol 
– volume: 11
  start-page: 370
  issue: 4
  year: 2016
  ident: 8202_CR89
  publication-title: Iran J Pathol
– volume: 4
  start-page: 083
  issue: 02
  year: 2012
  ident: 8202_CR91
  publication-title: J Lab Physicians
  doi: 10.4103/0974-2727.105587
– volume: 8
  start-page: 134
  issue: 3
  year: 2018
  ident: 8202_CR41
  publication-title: Egypt Germs
  doi: 10.18683/GERMS.2018.1140
– volume: 7
  start-page: 755
  issue: 9
  year: 2013
  ident: 8202_CR62
  publication-title: African J Microbiol Res
  doi: 10.5897/AJMR12.1430
– volume: 27
  start-page: 27
  issue: 4
  year: 2018
  ident: 8202_CR25
  publication-title: Egypt J Med Microbiol
  doi: 10.12816/0053809
– volume: 96
  start-page: 1
  issue: 1
  year: 2021
  ident: 8202_CR67
  publication-title: J Egypt Public Health Assoc
  doi: 10.1186/s42506-020-00065-8
– volume: 48
  start-page: 14
  year: 2017
  ident: 8202_CR24
  publication-title: J Microbiol N Egypt J Microbiol
– volume: 13
  start-page: 1239
  issue: 8
  year: 2014
  ident: 8202_CR74
  publication-title: Trop J Pharm Res
  doi: 10.4314/tjpr.v13i8.7
– volume: 36
  start-page: 534
  issue: 5
  year: 2015
  ident: 8202_CR8
  publication-title: Infect Control Hosp Epidemiol
  doi: 10.1017/ICE.2015.22
– ident: 8202_CR11
– volume: 27
  start-page: 27
  issue: 1
  year: 2009
  ident: 8202_CR12
  publication-title: Indian J Med Microbiol
  doi: 10.1016/S0255-0857(21)01748-5
– volume: 7
  start-page: 796
  issue: 11
  year: 2013
  ident: 8202_CR44
  publication-title: Egypt J Infect Dev Ctries
  doi: 10.3855/jidc.3105
– volume: 39
  start-page: e61
  issue: 9
  year: 2011
  ident: 8202_CR39
  publication-title: Am J Infect Control
  doi: 10.1016/J.AJIC.2011.04.009
– volume: 15
  start-page: 404
  issue: 4
  year: 2014
  ident: 8202_CR45
  publication-title: Surg Infect
  doi: 10.1089/SUR.2013.212
– volume: 45
  start-page: e99
  issue: 9
  year: 2017
  ident: 8202_CR80
  publication-title: Am J Infect Control
  doi: 10.1016/J.AJIC.2017.03.013
– volume: 10
  start-page: 1
  issue: 5
  year: 2015
  ident: 8202_CR82
  publication-title: Microbiol Res J Int
  doi: 10.9734/BMRJ/2015/15477
– volume: 28
  start-page: 971
  issue: 4
  year: 2019
  ident: 8202_CR56
  publication-title: Comp Clin Path
  doi: 10.1007/S00580-018-2858-3/TABLES/1
– volume: 6
  start-page: 4
  issue: 1
  year: 2016
  ident: 8202_CR31
  publication-title: Int Arab J Antimicrob Agents
  doi: 10.3823/784
– volume: 62
  start-page: 73
  issue: 1
  year: 2022
  ident: 8202_CR83
  publication-title: Egypt J Bot
  doi: 10.21608/EJBO.2021.47561.1576
– volume: 20
  start-page: 127
  issue: 2
  year: 2011
  ident: 8202_CR66
  publication-title: Egypt J Med Microbiol
– volume: 27
  start-page: 1190
  issue: 9
  year: 2021
  ident: 8202_CR13
  publication-title: Microb Drug Resist
  doi: 10.1089/mdr.2020.0361
– volume: 75
  start-page: e14081
  issue: 6
  year: 2021
  ident: 8202_CR84
  publication-title: Int J Clin Pract
  doi: 10.1111/ijcp.14081
– volume: 6
  start-page: 341
  issue: 5
  year: 2014
  ident: 8202_CR88
  publication-title: Iran J Microbiol
– volume: 14
  start-page: 56
  issue: 1
  year: 2022
  ident: 8202_CR52
  publication-title: Iran J Microbiol
  doi: 10.18502/ijm.v14i1.8802
– volume: 26
  start-page: 111
  issue: 2
  year: 2017
  ident: 8202_CR55
  publication-title: Egypt J Med Microbiol
  doi: 10.12816/0046236
– ident: 8202_CR38
  doi: 10.1093/qjmed/hcy200.117
– volume: 10
  start-page: 3900
  issue: 1
  year: 2020
  ident: 8202_CR6
  publication-title: Sci Rep
  doi: 10.1038/s41598-020-60825-6
– volume: 20
  start-page: 273
  issue: 04
  year: 2014
  ident: 8202_CR33
  publication-title: East Mediterr Heal J
  doi: 10.26719/2014.20.4.273
– volume: 25
  start-page: 93
  issue: 2
  year: 2016
  ident: 8202_CR68
  publication-title: Zagazig J Pharm Sci
  doi: 10.21608/zjps.2016.38183
– volume: 62
  start-page: 94
  issue: 2
  year: 2016
  ident: 8202_CR43
  publication-title: Cell Mol Biol (Noisy-le-grand)
  doi: 10.14715/cmb/2016.62.2.16
– volume: 16
  start-page: 426
  issue: 5
  year: 2012
  ident: 8202_CR26
  publication-title: Brazilian J Infect Dis
  doi: 10.1016/J.BJID.2012.08.004
– volume: 10
  start-page: 295
  issue: 4
  year: 2020
  ident: 8202_CR36
  publication-title: Germs
  doi: 10.18683/GERMS.2020.1221
– volume: 4
  start-page: S293
  year: 2014
  ident: 8202_CR92
  publication-title: Asian Pac J Trop Biomed
  doi: 10.12980/APJTB.4.2014C423
– ident: 8202_CR4
– volume: 4
  start-page: 16
  year: 2016
  ident: 8202_CR42
  publication-title: Egypt J Glob Antimicrob Resist
  doi: 10.1016/J.JGAR.2015.11.010
– volume: 5
  start-page: 0
  issue: (4)
  year: 2014
  ident: 8202_CR54
  publication-title: Arch Clin Microbiol
– volume: 12
  start-page: 1093
  issue: 3
  year: 2018
  ident: 8202_CR17
  publication-title: Egypt J PurE Appl Microbiol
  doi: 10.22207/JPaM.12.3.07
– ident: 8202_CR47
  doi: 10.2174/18742858-v16-e2204210
– volume: 15
  start-page: 1010
  issue: 5
  year: 2012
  ident: 8202_CR48
  publication-title: Iran J Basic Med Sci
– volume: 71
  start-page: 1860
  issue: 7
  year: 2016
  ident: 8202_CR94
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkw052
– volume: 7
  start-page: 1598
  issue: 16
  year: 2013
  ident: 8202_CR27
  publication-title: African J Microbiol Res
  doi: 10.5897/AJMR12.2333
– volume: 67
  start-page: 897
  issue: 8
  year: 2014
  ident: 8202_CR15
  publication-title: J Clin Epidemiol
  doi: 10.1016/J.JCLINEPI.2014.03.003
– volume: 13
  start-page: 855
  issue: 2
  year: 2019
  ident: 8202_CR29
  publication-title: J Pure Appl Microbiol
  doi: 10.22207/JPAM.13.2.21
– volume: 2
  start-page: 30
  issue: 1
  year: 2022
  ident: 8202_CR65
  publication-title: Azhar Int J Pharm Med Sci
  doi: 10.21608/AIJPMS.2021.69608.1058
– volume: 6
  start-page: 50
  issue: 2
  year: 2021
  ident: 8202_CR79
  publication-title: J Appl Vet Sci
  doi: 10.21608/JAVS.2021.159379
– volume: 15
  start-page: 797
  issue: 4
  year: 2006
  ident: 8202_CR73
  publication-title: Egyptian J Med Microbiol
– volume: 3
  start-page: 36
  issue: 2
  year: 2022
  ident: 8202_CR46
  publication-title: J Adv Med Pharm Res
– volume: 55
  start-page: 31
  issue: 1
  year: 2015
  ident: 8202_CR28
  publication-title: Egypt J Bot
  doi: 10.21608/EJBO.2015.223
– volume: 7
  start-page: 2438
  issue: 21
  year: 2013
  ident: 8202_CR86
  publication-title: African J Microbiol Res
  doi: 10.5897/ajmr2013.2525
– volume: 11
  start-page: 11
  year: 2020
  ident: 8202_CR49
  publication-title:  Int J Prev Med
  doi: 10.4103/ijpvm.IJPVM_320_18
– volume: 29
  start-page: 812
  issue: 4
  year: 2016
  ident: 8202_CR21
  publication-title: Menoufia Med J
  doi: 10.4103/1110-2098.202519
– volume: 2
  start-page: 715
  issue: 4
  year: 2021
  ident: 8202_CR40
  publication-title: Microbes Infect Dis
  doi: 10.21608/MID.2020.41062.1057
– volume: 24
  start-page: 349
  issue: 6
  year: 2017
  ident: 8202_CR81
  publication-title: Eur J Hosp Pharm
  doi: 10.1136/EJHPHARM-2016-001032
– volume: 3
  start-page: 294
  issue: 2
  year: 2019
  ident: 8202_CR18
  publication-title: Arch Pharm Sci Ain Shams Univ
  doi: 10.21608/APS.2019.17391.1014
– volume: 60
  start-page: 2273
  issue: 4
  year: 2016
  ident: 8202_CR93
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.02803-15
– volume: 18
  start-page: 97
  issue: 4
  year: 2009
  ident: 8202_CR69
  publication-title: EJMM-Egyptian J Med Microbiol
– volume: 3
  start-page: 910
  issue: 4
  year: 2022
  ident: 8202_CR63
  publication-title: Microbes Infect Dis
  doi: 10.21608/MID.2022.155274.1366
– volume: 29
  start-page: 97
  issue: 3
  year: 2020
  ident: 8202_CR72
  publication-title: Egypt J Med Microbiol
  doi: 10.51429/EJMM29313
– volume: 59
  start-page: 29
  issue: 1
  year: 2019
  ident: 8202_CR77
  publication-title: Egypt J Bot
  doi: 10.21608/EJBO.2018.4221.1187
– volume: 25
  start-page: 39
  issue: 1
  year: 2016
  ident: 8202_CR16
  publication-title: Zagazig J Pharm Sci
  doi: 10.21608/ZJPS.2016.38164
– volume: 25
  start-page: 101334
  year: 2021
  ident: 8202_CR20
  publication-title: Egypt. Gene Reports
  doi: 10.1016/j.genrep.2021.101334
– volume: 11
  start-page: 16071
  issue: 94
  year: 2016
  ident: 8202_CR90
  publication-title: African J Biotechnol
  doi: 10.4314/ajb.v11i94
– volume: 09
  start-page: 127
  issue: 03
  year: 2019
  ident: 8202_CR57
  publication-title: Open J Med Microbiol
  doi: 10.4236/OJMM.2019.93013
– volume: 158
  start-page: 513
  issue: 2
  year: 1984
  ident: 8202_CR1
  publication-title: J Bacteriol
  doi: 10.1128/JB.158.2.513-516.1984
– volume: 113
  start-page: 385
  year: 2017
  ident: 8202_CR19
  publication-title: Microb Pathog
  doi: 10.1016/J.MICPATH.2017.11.021
– ident: 8202_CR3
– volume: 1
  start-page: 106
  issue: 1
  year: 2009
  ident: 8202_CR61
  publication-title: Int J Immunol Stud
  doi: 10.1504/IJIS.2009.023564
– volume: 53
  start-page: 79
  issue: 1
  year: 2010
  ident: 8202_CR87
  publication-title: Indian J Pathol Microbiol
  doi: 10.4103/0377-4929.59189
SSID ssj0017829
Score 2.4944396
SecondaryResourceType review_article
Snippet Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen that causes severe morbidity and mortality worldwide. For the establishment...
Background Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen that causes severe morbidity and mortality worldwide. For the...
BackgroundMethicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen that causes severe morbidity and mortality worldwide. For the...
Abstract Background Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen that causes severe morbidity and mortality worldwide. For...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 263
SubjectTerms Analysis
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Antibiotics
Antimicrobial agents
Bacterial Proteins - genetics
Cefoxitin
Cefoxitin - therapeutic use
Cefoxitin disc diffusion
Clinical isolates
Diffusion
Diffusion rate
Disease control
Disease susceptibility
Dosage and administration
Drug resistance
Drug resistance in microorganisms
Egypt
Egypt - epidemiology
Epidemiology
Health aspects
Hospital costs
Humans
Infectious diseases
Linezolid
Linezolid - pharmacology
Linezolid - therapeutic use
Literature reviews
MecA protein
Medical personnel
Meta-analysis
Methicillin
Methicillin-resistant Staphylococcus aureus
Methicillin-Resistant Staphylococcus aureus - genetics
Microbial Sensitivity Tests
Morbidity
Mortality
MRSA
Nosocomial infection
Oxacillin
Oxacillin disc diffusion
Penicillin
Penicillin-Binding Proteins - genetics
Prevalence
Prevalence studies (Epidemiology)
Prevention
Prohibition
Public health
Risk factors
Sensitivity analysis
Staphylococcal Infections - drug therapy
Staphylococcus aureus
Staphylococcus aureus infections
Staphylococcus infections
Statistical analysis
Subgroups
Systematic review
Vancomycin
Vancomycin - pharmacology
Vancomycin - therapeutic use
SummonAdditionalLinks – databaseName: Open Access资源_DOAJ
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yD-KL-O3qKVEEFQnXJm3a-rbKHqdwCnee3FvIpy6srVzbh_VP869zJu3ubRH1RVhY2EyWdDKd-U07-Q0hz4KRWqY2Zy4UkKDI3DBTCMmcB29ZhlRXGp93HH-QR2fZ-_P8fKfVF9aEDfTAg-IONOQDpfUht4XIqsKV2thcA44JEPqNiOylEPM2ydT4_gDiXrU5IlPKgxa8cFExiE8MQx5nfBKGIlv_7z55JyhNCyZ3ItDhDXJ9hI50Piz5Jrni61vk6vH4cvw2-bm47Pa6pk2gm1OPqzVdgokBqnQUO0aDPDJxM8i0ET3WHQXICeqGuNZY27dU9xcevl4cn5zOX1JdO7rsWtr2bayBieW0a9o1FCHqj2a1dFEGiwmab2tYDIXPAvubvaaaXnJF0-GcDMVnv7gQzfRIiXKHnB0uPr09YmNrBmal4B2rIMprE0wQGjBa5rjw4Pq0LkTquXHC5VXpIVcpnS4tt6kwWWKSoI2xVcF9Iu6Svbqp_X1CQ1qVEdZZbjIBTs8V2Pc8kzaB7LM0M5JudkrZkbcc22esVMxfSqmG3VWwuyruruIz8mo75_vA2vFX6TdoAFtJZNyOP4AdqtEO1b_scEaeovko5NSosWjni-7bVr37-FnNMfEvAHv9Uej0ZCL0fBQKDVyo1eNBCVAXcnVNJPcnkuAZ7HR4Y8pq9Eyt4jCQ4-lkuOwn22GcidV2tW96lEkk4FaRJTNyb7D8rXIEQFLA6PDn5eSemGhvOlIvv0becpgoYGfTB_9D3w_JNR7v54xxuU_2uovePwJ82JnH0RX8AqQcZHY
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1tixMxEA56gggieupZPSWKoCLhdpN9yfpFqvQ4hSrceXLfQl52z0LdPbvbD_Wn-eucyabtLeJBodBMSjaTmXlmdjJDyMvKZDqLbcpclYODkqWGmVxkzJWgLWUV60JjvGP6JTs6TT6fpWch4NaGtMq1TvSK2jUWY-QHXMZYmkom_P3FL4Zdo_DtamihcZ3cwNJleKrzs43DFYP1K9YXZWR20IIuzgsGVoqh4eOMD4yRr9n_r2a-ZJqGaZOX7NDhXXInAEg67jl-j1wr611ycxpeke-S230gjvb3i-6TP5NtD9gVbSq6vgs5X9EZHDzAmo5iH2mYj_W5GfjfiCnrjgIQBSaAtWusXbZULxclfL2eHp-M31BdOzrrWtouW58Z45NsV7RrKALX38185jwNphg0P1ewOAqfCXY9e0c13VaQpv3tGYoRYVyIZjoUSnlATg8n3z4esdCwgdlM8I4VYPu1qUwlNCC3xHFRgkLUOhdxyY0TLi1kCR6MdFpabmNhkshElTbGFjkvI_GQ7NRNXT4itIoL6cGe5SYRoApdjt3Qk8xG4JNKMyLxmnPKhmrm2FRjrrxXIzPVc1sBt5XntuIj8nYz56Kv5XEl9Qc8EBtKrMPtf2gW5yqItdLgrUpbVqnNRVLkTmpjUw0ouwJgakQ6Ii_wOCmstFFjKs-5Xrat-vT1uxpjOCAHRPZfopPjAdGrQFQ18KBWh-sTsF1YwWtAuT-gBH1hh8Pro62CvmrVVrpG5PlmGGdiDl5dNkukiTJAsyKJRmSvl4TN5ggAqoDc4c_lQEYGuzccqWc_fDVzmCiAs_Hjq9f1hNziXnITxrN9stMtluVTwIOdeeaF_i-ZOmC9
  priority: 102
  providerName: ProQuest
Title Epidemiology of clinically isolated methicillin-resistant Staphylococcus aureus (MRSA) and its susceptibility to linezolid and vancomycin in Egypt: a systematic review with meta-analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/37101125
https://www.proquest.com/docview/2815558842
https://www.proquest.com/docview/2806993340
https://pubmed.ncbi.nlm.nih.gov/PMC10134521
https://doaj.org/article/a9988cef5c73497d8abc5a115f456b35
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ti9NAEF7OOxC_iO9Wz7KKoCKrSTbJbgSR9uhxCj2l50nxy7K7Sc5CTbRJwPrT_HXObNP2gqefhJJCd7YkO2_PbGZnCHmcm1jHvo1YmgsIUOLIMCN4zNIMrKXMfZ1o3O8YH8dHp-G7aTTdIet2R-0CVheGdthP6nQxf_Hj-_INKPxrp_AyflmBjRUJA-_D0KEFDEzyHngmgR0NxuH2rQJ4w2R9cObCeR3n5Gr4_2mpz7mqbhrlOb90eI1cbQElHawk4DrZyYob5PK4fWV-k_wabXvALmmZ0_VZyPmSzkDwAGumFPtIAz3W52YQfyOmLGoKQBSYAN6utLapqG4WGXw9HU9OBs-oLlI6qytaNZXLjHFJtktalxSB689yPksdDaYYlF-XcDMUPiPsevaKarqtIE1Xp2co7gjjjWim20Ipt8jp4ejjwRFrGzYwG_OgZgn4fm1yk3MNyC1MA56BQdRacD8LTMrTKJEZRDAy1dIG1ucm9IyXa2NsIoLM47fJblEW2V1Ccz-RDuzZwIQcTGEqsBt6GFsPYlJpesRfc0rZtpo5NtWYKxfVyFituKuAu8pxVwU98nwz59uqlsc_qYcoABtKrMPtfigXZ6pVa6UhWpU2yyMreJiIVGpjIw0oOwdganjUI49QfBRW2igwledMN1Wl3r7_pAa4HSAAkf2V6GTSIXrSEuUlPKjV7fEJWC6s4NWh3O9Qgr2w3eG1KKu1uqkABiI8swyP_XAzjDMxB6_IygZpvBjQLA-9HrmzkvzN4nAAqoDc4c9lRyc6q9cdKWZfXDVzmMiBs_69_7He98mVwOlzyIJ4n-zWiyZ7AKixNn1ySUwFXOWB3yd7w9Hxh0nf7cD0nZGA62T4-TdPqHFX
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV17axQxEA-1ggoiWl-nVaMoKhK6m-wjK4ic9cqd7VXoQ_pfTLK79eDcrd095PxQfgA_nTP7uOsi9r_CwcFlsuQyk5nfZOdByPPUBDpwrc_iNAQHJfANM6EIWJyAtpSpqyON9x3j3WB46H068o9WyO82FwbDKludWCnqOLd4R77BpYulqaTH35_8YNg1Ct-uti00arHYTuY_wWUr3o0-An9fcL41ONgcsqarALOB4CWLwEBpk5pUaIAXXsxFAqdW61C4CTexiP1IJgCzZayl5dYVxnOMk2pjbBTyxBHw3EvksifgaGJm-uYipMQFaxu1iTky2ChA94cRA6vI0NByxjvGr-oR8K8lOGMKu2GaZ-ze1k1yowGstF9L2C2ykmRr5Mq4eSW_Rq7XF3-0zme6Tf4Mlj1n5zRPaZt7OZ3TCQg6YNuYYt9qmI_1wBn4-4hhs5IC8AWmg3XNrZ0VVM9OE_h6Nd7b77-mOovppCxoMSuqSJwqqHdOy5wiUP6VTydxRYMhDfn3OSyOwmeAXdbeUk2XFatpna1D8QYaF6KZbgqz3CGHF8LKu2Q1y7PkPqGpG8kKXFpuPAGqNw6x-7oXWAd8YGl6xG05p2xTPR2beExV5UXJQNXcVsBtVXFb8R55s5hzUtcOOZf6AwrEghLrflc_5KfHqlEjSoN3LG2S-jYUXhTGUhvra0D1KQBhI_weeYbipLCyR4ahQ8d6VhRq9PmL6uP1QwgI8L9E-3sdopcNUZrDH7W6SdeA7cKKYR3K9Q4l6CfbHW5FWzX6sVDL09wjTxfDOBNj_rIknyGNEwB6Fp7TI_fqk7DYHAHAGDwFeLjsnJHO7nVHssm3qno6TBTAWffB-et6Qq4OD8Y7ame0u_2QXOPVKfYYD9bJank6Sx4BFi3N40oBUPL1ojXOX5oNnjY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Epidemiology+of+clinically+isolated+methicillin-resistant+Staphylococcus+aureus+%28MRSA%29+and+its+susceptibility+to+linezolid+and+vancomycin+in+Egypt%3A+a+systematic+review+with+meta-analysis&rft.jtitle=BMC+infectious+diseases&rft.au=Ahmed+Azzam&rft.au=Heba+Khaled&rft.au=Maha+Mosa&rft.au=Neveen+Refaey&rft.date=2023-04-26&rft.pub=BMC&rft.eissn=1471-2334&rft.volume=23&rft.issue=1&rft.spage=1&rft.epage=15&rft_id=info:doi/10.1186%2Fs12879-023-08202-2&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_a9988cef5c73497d8abc5a115f456b35
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon